2 results
Approved WMORecruiting
Primary Objective:To compare the clinical benefit of abiraterone acetate plus prednisone versus placebo plus prednisone in patients with chemotherapy-naïve castration-resistant prostate cancer (CRPC) who are asymptomatic or mildly symptomatic.…
Approved WMOCompleted
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.